<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00610727</url>
  </required_header>
  <id_info>
    <org_study_id>AMDC 04-001</org_study_id>
    <secondary_id>Amended September 8, 2004</secondary_id>
    <nct_id>NCT00610727</nct_id>
  </id_info>
  <brief_title>Staccato Prochlorperazine Single Dose PK Study</brief_title>
  <official_title>Tolerability, Safety and Pharmacokinetics of a Single Dose of Staccatoâ„¢ Prochlorperazine for Inhalation in Normal, Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alexza Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>PPD</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Alexza Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study was to evaluate the tolerability, safety, and pharmacokinetics of
      inhaled prochlorperazine
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The objective of this study was to evaluate the tolerability, safety, and pharmacokinetics of
      a single, inhaled dose of prochlorperazine (PCZ), administered as 1 or 2 puffs in healthy
      young volunteers.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2004</start_date>
  <completion_date type="Actual">October 2004</completion_date>
  <primary_completion_date type="Actual">October 2004</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Stage 1: open-label, single-dose stage with 3 treatment periods divided into 2 phases Stage 2: double-blind, placebo-controlled, dose-escalation treatment period</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Stage 2 was a double-blind, placebo-controlled, 4 step dose-escalation trial</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Time to Peak (Tmax)</measure>
    <time_frame>24 hours</time_frame>
    <description>Time from dose to peak prochlorperazine concentration</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Absolute Bioavailability of Inhaled Prochlorperazine</measure>
    <time_frame>24 hours</time_frame>
    <description>Absolute bioavailability of inhaled prochlorperazine via AUC infinity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dose Proportionality of Inhaled Prochlorperazine by Power Analysis</measure>
    <time_frame>24 hours</time_frame>
    <description>Dose proportionality by power analysis examines the linear regression of the log-AUC versus log-Dose on a by-patient basis across all doses administered. The slope and 90% confidence interval (CI) provide a clear, quantitative (best practices) assessment of the relationship of drug delivered to dose administered. The units on such analyses are generally those of slope (rise over run), with 1.000 being &quot;perfect&quot;. Although any positive slope might be considered clinically useful, a 90% CI within the criteria of 0.800-1.250 may be considered a delivery system which is &quot;as good as it gets&quot;.</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">54</enrollment>
  <condition>Migraine</condition>
  <arm_group>
    <arm_group_label>Inhaled prochlorperazine 0.625 mg vs IV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Prochlorperazine 0.5 mg IV over 5 sec crossover Inhaled prochlorperazine 0.625 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Inhaled prochlorperazine 1.25 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Inhaled Staccato prochlorperazine 1.25 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Inhaled prochlorperazine 2.5 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Inhaled Staccato prochlorperazine 2.5 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Inhaled prochlorperazine 5 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Inhaled Staccato prochlorperazine 5 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Inhaled prochlorperazine 10 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Inhaled Staccato prochlorperazine 10 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>inhaled Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>inhaled Staccato Placebo (0 mg)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prochlorperazine 0.5 mg IV over 5 sec</intervention_name>
    <description>IV Prochlorperazine for bioavailability</description>
    <arm_group_label>Inhaled prochlorperazine 0.625 mg vs IV</arm_group_label>
    <other_name>PCZ</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Inhaled prochlorperazine 0.625 mg</intervention_name>
    <description>Inhaled Staccato Prochlorperazine 0.625 mg</description>
    <arm_group_label>Inhaled prochlorperazine 0.625 mg vs IV</arm_group_label>
    <other_name>PCZ</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Inhaled prochlorperazine 1.25 mg</intervention_name>
    <description>Inhaled Staccato Prochlorperazine 1.25 mg</description>
    <arm_group_label>Inhaled prochlorperazine 1.25 mg</arm_group_label>
    <other_name>PCZ</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Inhaled prochlorperazine 2.5 mg</intervention_name>
    <description>Inhaled Staccato Prochlorperazine 2.5 mg</description>
    <arm_group_label>Inhaled prochlorperazine 2.5 mg</arm_group_label>
    <other_name>PCZ</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Inhaled prochlorperazine 5 mg</intervention_name>
    <description>InhaledStaccato Prochlorperazine 5 mg</description>
    <arm_group_label>Inhaled prochlorperazine 5 mg</arm_group_label>
    <other_name>PCZ</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Inhaled prochlorperazine 10 mg</intervention_name>
    <description>InhaledStaccato Prochlorperazine 10 mg</description>
    <arm_group_label>Inhaled prochlorperazine 10 mg</arm_group_label>
    <other_name>PCZ</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Inhaled placebo</intervention_name>
    <description>Inhaled Staccato Placebo (0 mg)</description>
    <arm_group_label>inhaled Placebo</arm_group_label>
    <other_name>ADASUVE placebo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prochlorperazine 10 mg IV over 5 sec</intervention_name>
    <description>Prochlorperazine 10 mg IV over 5 sec for patient qualification</description>
    <arm_group_label>Inhaled prochlorperazine 0.625 mg vs IV</arm_group_label>
    <other_name>PCZ</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects will be male or female subjects between the ages 18 to 45 years, inclusive in
             good general health as determined by medical history, physical examination, 12-lead
             ECG, spirometry, blood chemistry profile, hematology, urinalysis and in the opinion of
             the Principal Investigator.

        Exclusion Criteria:

          -  Subjects with a known history of allergy or intolerance to phenothiazines or related
             drugs or who have any disease, by history, physical examination, or laboratory
             abnormalities that in the investigator's opinion, would present undue risk to the
             subject, or may confound the interpretation of study results.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniel A Spyker, MD</last_name>
    <role>Study Director</role>
    <affiliation>Alexza Pharmaceuticals, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>PPD Phase I Clinic</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78704-7016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Avram MJ, Spyker DA, Henthorn TK, Cassella JV. The pharmacokinetics and bioavailability of prochlorperazine delivered as a thermally generated aerosol in a single breath to volunteers. Clin Pharmacol Ther. 2009 Jan;85(1):71-7. doi: 10.1038/clpt.2008.184. Epub 2008 Oct 1.</citation>
    <PMID>18830225</PMID>
  </reference>
  <verification_date>September 2008</verification_date>
  <study_first_submitted>January 28, 2008</study_first_submitted>
  <study_first_submitted_qc>January 28, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 8, 2008</study_first_posted>
  <results_first_submitted>March 10, 2017</results_first_submitted>
  <results_first_submitted_qc>January 26, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">November 5, 2018</results_first_posted>
  <last_update_submitted>January 26, 2018</last_update_submitted>
  <last_update_submitted_qc>January 26, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">November 5, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Migraine, Prochlorperazine aerosol</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Migraine Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prochlorperazine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>IPD submitted to regulatory authorities. Others may contact Alexza Pharmaceuticals, Inc. Please send your request to ClinicalTrialsInfo@alexza.com</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Qualification &amp; Crossover Arm, Inhaled Prochlorperazine vs IV</title>
          <description>Prochlorperazine 10 mg IV over 2 min qualification
Prochlorperazine 0.5 mg IV over 5 sec crossover Inhaled prochlorperazine 0.625 mg
ALL SUBJECTS RECEIVED ALL TREATMENT</description>
        </group>
        <group group_id="P2">
          <title>Inhaled Prochlorperazine 1.25 mg</title>
          <description>Inhaled Staccato prochlorperazine 1.25 mg
Inhaled prochlorperazine 1.25 mg: Inhaled Staccato Prochlorperazine 1.25 mg</description>
        </group>
        <group group_id="P3">
          <title>Inhaled Prochlorperazine 2.5 mg</title>
          <description>Inhaled Staccato prochlorperazine 2.5 mg
Inhaled prochlorperazine 2.5 mg: Inhaled Staccato Prochlorperazine 2.5 mg</description>
        </group>
        <group group_id="P4">
          <title>Inhaled Prochlorperazine 5 mg</title>
          <description>Inhaled Staccato prochlorperazine 5 mg
Inhaled prochlorperazine 5 mg: InhaledStaccato Prochlorperazine 5 mg</description>
        </group>
        <group group_id="P5">
          <title>Inhaled Prochlorperazine 10 mg</title>
          <description>Inhaled Staccato prochlorperazine 10 mg
Inhaled prochlorperazine 10 mg: InhaledStaccato Prochlorperazine 10 mg</description>
        </group>
        <group group_id="P6">
          <title>Inhaled Placebo</title>
          <description>inhaled Staccato Placebo (0 mg)
Inhaled placebo: Inhaled Staccato Placebo (0 mg)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="8"/>
                <participants group_id="P5" count="8"/>
                <participants group_id="P6" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="8"/>
                <participants group_id="P5" count="8"/>
                <participants group_id="P6" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Safety Population</population>
      <group_list>
        <group group_id="B1">
          <title>Qualification &amp; Crossover, Inhaled Prochlorperazine vs IV</title>
          <description>Prochlorperazine 10 mg IV over 2 min qualification
Prochlorperazine 0.5 mg IV over 5 sec crossover Inhaled prochlorperazine 0.625 mg
ALL SUBJECTS RECEIVED ALL 3 TREATMENTS</description>
        </group>
        <group group_id="B2">
          <title>Inhaled Prochlorperazine 1.25 mg</title>
          <description>Inhaled Staccato prochlorperazine 1.25 mg
Inhaled prochlorperazine 1.25 mg: Inhaled Staccato Prochlorperazine 1.25 mg</description>
        </group>
        <group group_id="B3">
          <title>Inhaled Prochlorperazine 2.5 mg</title>
          <description>Inhaled Staccato prochlorperazine 2.5 mg
Inhaled prochlorperazine 2.5 mg: Inhaled Staccato Prochlorperazine 2.5 mg</description>
        </group>
        <group group_id="B4">
          <title>Inhaled Prochlorperazine 5 mg</title>
          <description>Inhaled Staccato prochlorperazine 5 mg
Inhaled prochlorperazine 5 mg: InhaledStaccato Prochlorperazine 5 mg</description>
        </group>
        <group group_id="B5">
          <title>Inhaled Prochlorperazine 10 mg</title>
          <description>Inhaled Staccato prochlorperazine 10 mg
Inhaled prochlorperazine 10 mg: InhaledStaccato Prochlorperazine 10 mg</description>
        </group>
        <group group_id="B6">
          <title>Inhaled Placebo</title>
          <description>inhaled Staccato Placebo (0 mg)
Inhaled placebo: Inhaled Staccato Placebo (0 mg)</description>
        </group>
        <group group_id="B7">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="14"/>
            <count group_id="B2" value="8"/>
            <count group_id="B3" value="8"/>
            <count group_id="B4" value="8"/>
            <count group_id="B5" value="8"/>
            <count group_id="B6" value="8"/>
            <count group_id="B7" value="54"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="8"/>
                    <measurement group_id="B5" value="8"/>
                    <measurement group_id="B6" value="8"/>
                    <measurement group_id="B7" value="54"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29.4" spread="7.86"/>
                    <measurement group_id="B2" value="25.1" spread="3.44"/>
                    <measurement group_id="B3" value="25" spread="4.57"/>
                    <measurement group_id="B4" value="26.4" spread="8.94"/>
                    <measurement group_id="B5" value="28.8" spread="10.2"/>
                    <measurement group_id="B6" value="23.5" spread="7.03"/>
                    <measurement group_id="B7" value="25.8" spread="7.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="4"/>
                    <measurement group_id="B6" value="4"/>
                    <measurement group_id="B7" value="26"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="4"/>
                    <measurement group_id="B6" value="4"/>
                    <measurement group_id="B7" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="8"/>
                    <measurement group_id="B5" value="8"/>
                    <measurement group_id="B6" value="8"/>
                    <measurement group_id="B7" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Time to Peak (Tmax)</title>
        <description>Time from dose to peak prochlorperazine concentration</description>
        <time_frame>24 hours</time_frame>
        <population>Pharmacokinetic Population</population>
        <group_list>
          <group group_id="O1">
            <title>0.5 mg 5 Sec IV</title>
            <description>0.5 mg 5 sec IV prochlorperazine</description>
          </group>
          <group group_id="O2">
            <title>0.625 mg Inhaled Prochlorperazine</title>
            <description>0.625 mg Inhaled prochlorperazine</description>
          </group>
          <group group_id="O3">
            <title>1.25 mg Inhaled</title>
            <description>1.25 mg Inhaled Prochlorperazine</description>
          </group>
          <group group_id="O4">
            <title>2.5 mg Inhaled</title>
            <description>2.5 mg Inhaled Prochlorperazine</description>
          </group>
          <group group_id="O5">
            <title>5 mg Inhaled</title>
            <description>5 mg Inhaled Prochlorperazine</description>
          </group>
          <group group_id="O6">
            <title>10 mg Inhaled</title>
            <description>10 mg Inhaled Prochlorperazine</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Peak (Tmax)</title>
          <description>Time from dose to peak prochlorperazine concentration</description>
          <population>Pharmacokinetic Population</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="8"/>
                <count group_id="O6" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.042" lower_limit="0.025" upper_limit="0.067"/>
                    <measurement group_id="O2" value="0.033" lower_limit="0.025" upper_limit="0.042"/>
                    <measurement group_id="O3" value="0.025" lower_limit="0.013" upper_limit="0.082"/>
                    <measurement group_id="O4" value="0.033" lower_limit="0.017" upper_limit="0.033"/>
                    <measurement group_id="O5" value="0.040" lower_limit="0.017" upper_limit="0.115"/>
                    <measurement group_id="O6" value="0.033" lower_limit="0.013" upper_limit="0.108"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Absolute Bioavailability of Inhaled Prochlorperazine</title>
        <description>Absolute bioavailability of inhaled prochlorperazine via AUC infinity</description>
        <time_frame>24 hours</time_frame>
        <population>Bioavailability crossover subjects, n=8</population>
        <group_list>
          <group group_id="O1">
            <title>Bioavailability Crossover Arm</title>
            <description>0.625 mg prochlorperazine crossover 0.5 mg via 5-second IV prochlorperazine</description>
          </group>
        </group_list>
        <measure>
          <title>Absolute Bioavailability of Inhaled Prochlorperazine</title>
          <description>Absolute bioavailability of inhaled prochlorperazine via AUC infinity</description>
          <population>Bioavailability crossover subjects, n=8</population>
          <units>Fraction absorbed</units>
          <param>Geometric Least Squares Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.98" lower_limit="0.73" upper_limit="1.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Dose Proportionality of Inhaled Prochlorperazine by Power Analysis</title>
        <description>Dose proportionality by power analysis examines the linear regression of the log-AUC versus log-Dose on a by-patient basis across all doses administered. The slope and 90% confidence interval (CI) provide a clear, quantitative (best practices) assessment of the relationship of drug delivered to dose administered. The units on such analyses are generally those of slope (rise over run), with 1.000 being &quot;perfect&quot;. Although any positive slope might be considered clinically useful, a 90% CI within the criteria of 0.800-1.250 may be considered a delivery system which is &quot;as good as it gets&quot;.</description>
        <time_frame>24 hours</time_frame>
        <population>Pharmacokinetic Population, n=40</population>
        <group_list>
          <group group_id="O1">
            <title>All Subjects Receiving Inhaled Prochloperazine</title>
            <description>0.625 mg, 8 subjects 1.25 mg, 8 subjects 2.5 mg, 8 subjects 5 mg, 8 subjects 10 mg, 8 subjects</description>
          </group>
        </group_list>
        <measure>
          <title>Dose Proportionality of Inhaled Prochlorperazine by Power Analysis</title>
          <description>Dose proportionality by power analysis examines the linear regression of the log-AUC versus log-Dose on a by-patient basis across all doses administered. The slope and 90% confidence interval (CI) provide a clear, quantitative (best practices) assessment of the relationship of drug delivered to dose administered. The units on such analyses are generally those of slope (rise over run), with 1.000 being &quot;perfect&quot;. Although any positive slope might be considered clinically useful, a 90% CI within the criteria of 0.800-1.250 may be considered a delivery system which is &quot;as good as it gets&quot;.</description>
          <population>Pharmacokinetic Population, n=40</population>
          <units>Slope of Power Regression</units>
          <param>Geometric Least Squares Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.089" lower_limit=".99" upper_limit="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events (AEs) were considered treatment related from the first exposure to study treatment until 30 days after the last treatment</time_frame>
      <desc>Adverse events (AEs) were assessed predose and Performed throughout the 24-hour period after dosing .</desc>
      <group_list>
        <group group_id="E1">
          <title>IV Prochlorperazine 10 mg</title>
          <description>Intravenous prochlorperazine 10 mg</description>
        </group>
        <group group_id="E2">
          <title>IV Prochlorperazine 0.5 mg</title>
          <description>Intravenous prochlorperazine 0.5 mg</description>
        </group>
        <group group_id="E3">
          <title>Inhaled Prochlorperazine 0.625</title>
          <description>Inhaled prochlorperazine 0.625 mg</description>
        </group>
        <group group_id="E4">
          <title>Inhaled Prochlorperazine 1.25 mg</title>
          <description>Inhaled Staccato prochlorperazine 1.25 mg</description>
        </group>
        <group group_id="E5">
          <title>Inhaled Prochlorperazine 2.5 mg</title>
          <description>Inhaled Staccato prochlorperazine 2.5 mg</description>
        </group>
        <group group_id="E6">
          <title>Inhaled Prochlorperazine 5 mg</title>
          <description>Inhaled Staccato prochlorperazine 5 mg</description>
        </group>
        <group group_id="E7">
          <title>Inhaled Prochlorperazine 10 mg</title>
          <description>Inhaled Staccato prochlorperazine 10 mg</description>
        </group>
        <group group_id="E8">
          <title>Inhaled Placebo</title>
          <description>inhaled Staccato Placebo (0 mg)</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (7.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="8"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Vision blurred</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Sensation of pressure in face</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Syncope vasovagal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Throat irritation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Executive VP, Research &amp; Development, Regulatory &amp; Quality</name_or_title>
      <organization>Alexza Pharmaceuticals, Inc</organization>
      <phone>650.944.7071</phone>
      <email>ClinicalTrialsInfo@alexza.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

